LuMind IDSC Statement on FDA Approval of Leqembi
Last week the FDA announced a full approval of a new drug called Leqembi to…
Kim WarrenJuly 13, 2023
Alzheimer’s Disease Research Focus: Updates on Current and Upcoming Clinical Trials
During this presentation, Dr. Jim Hendrix will discuss the recent research progress in Down syndrome…
The State of Alzheimer’s Research, with Dr Marcia Ratner & Dr James Hendrix
Dr. Marcia Ratner & Dr. James Hendrix discuss recent developments in Alzheimer’s research.Source: Dr. Marcia…
Rigsby RigsbyDecember 3, 2021
Why Patient Voices Are So Critical to the Development and Initial Approval of New Drugs
This blogpost from a former FDA insider on the power of the patient helps us…
Rigsby RigsbyOctober 27, 2021
Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab
On October 22, 2019, the biopharmaceutical company, Biogen, announced that they will be going to…
Rigsby RigsbyOctober 27, 2021
LuMind IDSC signs on to NTG statement re: Aduhelm
“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as…
Rigsby RigsbyOctober 27, 2021
LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage
LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage
LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group…
Rigsby RigsbyOctober 27, 2021
FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003
Today marks an important milestone in Alzheimer’s disease research with the approval by the FDA…
Rigsby RigsbyOctober 27, 2021
Progress in Alzheimer’s Disease Builds Renewed Interest in Research
In June of 2021, the FDA approved a new drug, Aduhelm, from the company Biogen…
Rigsby RigsbyOctober 27, 2021
Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer’s Disease
The NTG brought together a national panel of expert researchers and practitioners in the field…
Rigsby RigsbyOctober 20, 2021